Fig. 1From: Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trialsAssociation between sex and risk of severe (grade 3 or 4) rash stratified by study and treatmentBack to article page